JP2006515561A - Ａｐｏ−Ｂ４８及びＡｐｏ−Ｂ１００のアッセイのための組成物及び方法 - Google Patents

Ａｐｏ−Ｂ４８及びＡｐｏ−Ｂ１００のアッセイのための組成物及び方法 Download PDF

Info

Publication number
JP2006515561A
JP2006515561A JP2004514955A JP2004514955A JP2006515561A JP 2006515561 A JP2006515561 A JP 2006515561A JP 2004514955 A JP2004514955 A JP 2004514955A JP 2004514955 A JP2004514955 A JP 2004514955A JP 2006515561 A JP2006515561 A JP 2006515561A
Authority
JP
Japan
Prior art keywords
apo
antibody
sample
peptide
detecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004514955A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006515561A5 (enExample
Inventor
ナジブ，ジャミラ
マジド，ズーヘル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genfit SA
Original Assignee
Genfit SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit SA filed Critical Genfit SA
Publication of JP2006515561A publication Critical patent/JP2006515561A/ja
Publication of JP2006515561A5 publication Critical patent/JP2006515561A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Light Receiving Elements (AREA)
JP2004514955A 2002-06-19 2003-06-19 Ａｐｏ−Ｂ４８及びＡｐｏ−Ｂ１００のアッセイのための組成物及び方法 Pending JP2006515561A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0207542A FR2841249A1 (fr) 2002-06-19 2002-06-19 Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100
PCT/FR2003/001888 WO2004000884A2 (fr) 2002-06-19 2003-06-19 Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100

Publications (2)

Publication Number Publication Date
JP2006515561A true JP2006515561A (ja) 2006-06-01
JP2006515561A5 JP2006515561A5 (enExample) 2006-08-17

Family

ID=29719858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004514955A Pending JP2006515561A (ja) 2002-06-19 2003-06-19 Ａｐｏ−Ｂ４８及びＡｐｏ−Ｂ１００のアッセイのための組成物及び方法

Country Status (11)

Country Link
US (1) US20050152900A1 (enExample)
EP (1) EP1513878B1 (enExample)
JP (1) JP2006515561A (enExample)
AT (1) ATE356832T1 (enExample)
AU (1) AU2003267493A1 (enExample)
CA (1) CA2489057A1 (enExample)
DE (1) DE60312513T2 (enExample)
DK (1) DK1513878T3 (enExample)
ES (1) ES2283803T3 (enExample)
FR (1) FR2841249A1 (enExample)
WO (1) WO2004000884A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009531712A (ja) * 2006-03-23 2009-09-03 デ グスマン ブレイヤー、エメリタ アポリポタンパク質フィンガープリント技術
JP2010230660A (ja) * 2009-03-06 2010-10-14 Kyowa Medex Co Ltd 可溶性インターロイキン−２受容体定量用標準品

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005093415A1 (ja) * 2004-03-29 2008-02-14 株式会社シバヤギ アポリポタンパク質ｂ−４８の測定方法およびその用途
WO2007058588A1 (en) * 2005-11-18 2007-05-24 T.A.C Thrombosis And Coagulation Aktiebolag Monoclonal antibodies against apolipoprotein m
US8088593B2 (en) 2007-10-02 2012-01-03 Theranos, Inc. Modular point-of-care devices, systems, and uses thereof
EP2408812B1 (en) * 2009-03-17 2015-12-16 CardioVax, LLC Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis and related proteins, peptides and compositions
WO2011060329A1 (en) 2009-11-14 2011-05-19 Kuang-Yuh Chyu Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
US8506964B2 (en) 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
RU2013126628A (ru) 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер Иммуномодулирующие способы и системы для лечения и/или предотвращения аневризм
CA2817543A1 (en) 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
CN106323875B (zh) 2011-01-21 2019-07-09 西拉诺斯知识产权有限责任公司 样品使用最大化的系统和方法
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9268915B2 (en) 2011-09-25 2016-02-23 Theranos, Inc. Systems and methods for diagnosis or treatment
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
US9250229B2 (en) 2011-09-25 2016-02-02 Theranos, Inc. Systems and methods for multi-analysis
US11008628B1 (en) 2013-02-18 2021-05-18 Labrador Diagnostics Llc Systems and methods for analyte testing and laboratory oversight
US10401373B1 (en) 2013-02-18 2019-09-03 Theranos Ip Company, Llc Systems and methods for analyte testing and laboratory oversight
US10422806B1 (en) 2013-07-25 2019-09-24 Theranos Ip Company, Llc Methods for improving assays of biological samples
US11360107B1 (en) 2014-02-25 2022-06-14 Labrador Diagnostics Llc Systems and methods for sample handling
CN106053793A (zh) * 2016-06-20 2016-10-26 诺莱生物医学研究院（北京）有限公司 一种快速检测乳糜血的免疫层析试纸卡及其制备方法
WO2025111449A1 (en) * 2023-11-21 2025-05-30 Sun Diagnostics, Inc. Method and reagent to clear turbidity due to elevated triglycerides in a biological specimen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60193926A (ja) * 1984-03-15 1985-10-02 Tokyo Daigaku 単クローン性抗ヒトアポリポ蛋白質ｂ１００抗体
JPS617299A (ja) * 1984-06-20 1986-01-13 Dai Ichi Pure Chem Co Ltd ヒトアポリポ蛋白ｂ４８に高い特異性を有する単クローン性抗体
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009531712A (ja) * 2006-03-23 2009-09-03 デ グスマン ブレイヤー、エメリタ アポリポタンパク質フィンガープリント技術
JP2010230660A (ja) * 2009-03-06 2010-10-14 Kyowa Medex Co Ltd 可溶性インターロイキン−２受容体定量用標準品
JP2014167490A (ja) * 2009-03-06 2014-09-11 Kyowa Medex Co Ltd 可溶性インターロイキン−２受容体定量用標準品

Also Published As

Publication number Publication date
WO2004000884A2 (fr) 2003-12-31
DE60312513D1 (de) 2007-04-26
FR2841249A1 (fr) 2003-12-26
ES2283803T3 (es) 2007-11-01
ATE356832T1 (de) 2007-04-15
DK1513878T3 (da) 2007-07-16
AU2003267493A1 (en) 2004-01-06
US20050152900A1 (en) 2005-07-14
DE60312513T2 (de) 2007-12-06
CA2489057A1 (fr) 2003-12-31
EP1513878A2 (fr) 2005-03-16
EP1513878B1 (fr) 2007-03-14
WO2004000884A3 (fr) 2004-04-08

Similar Documents

Publication Publication Date Title
US20050152900A1 (en) Compositions and methods for apo-b48 and apo-b100 assay
DK1546734T3 (en) MONOCLONAL ANTIBODIES AGAINST N-11-TRUNCATED AMYLOID BETA, COMPOSITIONS, PROCEDURES AND APPLICATIONS
US5733549A (en) Peptides including amino acid sequences selected from lipoprotein (a) and apolipoprotein (a), antibodies recognizing these amino acid sequences, and methods of determination using these antibodies
EP2159577B1 (en) Novel marker for arteriosclerotic disease
JP4413179B2 (ja) 免疫学的粒子凝集反応方法
JP4163764B2 (ja) 免疫学的粒子凝集反応方法
JP2012058048A (ja) ペリオスチン測定の正確性の改善方法
EP2692735B1 (en) Antibody reacting with native cochlin-tomoprotein (ctp) and method for measuring ctp using same
JP5055598B2 (ja) ヒトｈｍｇ−１に特異的に結合する抗体を用いるヒトｈｍｇ−１の免疫学的測定方法及び免疫学的測定試薬
JP2005502029A (ja) アポｂおよび非アポｂ含有粒子中のアポｃｉｉｉを測定する新規な方法
JP3713585B2 (ja) 変性又は修飾リポタンパク質（ａ）に結合する抗体及びこの抗体を用いる測定法
WO2012141792A2 (en) Adiponectin receptor c-terminal fragments (ctf)-immunoglobulin
JP5852433B2 (ja) ソルチリンによる動脈硬化の判定方法
EP3760641A1 (en) Monoclonal antibody against apoa4, immunoassay method, and kit for measurement
Najib Compositions and methods for apo-b48 and apo-b100 assay
JP2005502711A (ja) Ａａ４ｒｐアッセイのための組成物および方法
WO2002098915A2 (en) Compositions and methods for detecting or regulating cholesteryl ester transfer protein
US20090136985A1 (en) Vascular Aging-Predicting Factor and Utilization of the Same
EP2020417A1 (en) Prostasin partial peptide and anti-prostasin antibody
US20110230649A1 (en) Compositions and Methods for Redox Modulated Proteins
JP2021063020A (ja) Ｈｍｇｂ１の分解産物に結合する抗体、ｈｍｇｂ１分解産物の測定方法及びｈｍｇｂ１分解産物の測定試薬
JPH0977798A (ja) 抗コレステリルエステル転送蛋白抗体
JPWO1994004563A1 (ja) リポタンパク質（ａ）及びアポリポタンパク質（ａ）より選択されたアミノ酸配列を含むペプチド、これらのアミノ酸配列を認識する抗体、並びにこれらの抗体を用いる測定法
JPH06113880A (ja) モノクローナル抗体及びこれを用いたリポプロティンスモールａの測定方法
JP2007316009A (ja) アドレノメデュリン前駆体ｃ末端ペプチドの濃度の上昇を指標として循環器疾患又は炎症性疾患を診断する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060619

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20060619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090512

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091027